Watch the webinar here.
In April 2022, the FDA released Draft Guidance entitled ‘Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials’.
It recommends developing and submitting a Race and Ethnicity Diversity Plan to increase participation in clinical trials by populations currently underrepresented in such studies.
Join industry executives, patient advocates, academic center representatives, and regulatory experts in a discussion about the implications of the Draft Guidance, emerging best practices in supporting diversity in clinical trials, and developing opportunities for establishing sustainable relationships with underrepresented communities.
What will be covered in this Webinar:
- Understand the content of the Draft Guidance, the potential impact and implications for industry and impacted communities.
- Learn about successful efforts in improving diversity in clinical trials
- Consider strategies for developing long lasting, mutually beneficial relationships with underserved communities.